NGM Biopharmaceuticals Inc (DELISTED) (NGM:DL)
1.54
0.00 (0.00%)
USD |
NASDAQ |
Apr 05, 16:00
NGM Biopharmaceuticals Free Cash Flow (Quarterly): -23.15M for Dec. 31, 2023
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | -23.15M |
| September 30, 2023 | -27.45M |
| June 30, 2023 | -40.35M |
| March 31, 2023 | -42.50M |
| December 31, 2022 | -30.84M |
| September 30, 2022 | -28.46M |
| June 30, 2022 | -50.97M |
| March 31, 2022 | -36.02M |
| December 31, 2021 | -18.47M |
| September 30, 2021 | -9.555M |
| June 30, 2021 | -24.50M |
| March 31, 2021 | -22.38M |
| Date | Value |
|---|---|
| December 31, 2020 | -20.31M |
| September 30, 2020 | -25.32M |
| June 30, 2020 | -20.06M |
| March 31, 2020 | -19.68M |
| December 31, 2019 | -15.66M |
| September 30, 2019 | -6.851M |
| June 30, 2019 | -8.286M |
| March 31, 2019 | -13.87M |
| December 31, 2018 | 6.901M |
| September 30, 2018 | -6.525M |
| June 30, 2018 | -8.319M |
| March 31, 2018 | -5.498M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-50.97M
Minimum
Jun 2022
-6.851M
Maximum
Sep 2019
-24.78M
Average
-23.15M
Median
Dec 2023
Free Cash Flow (Quarterly) Benchmarks
| Catalent Inc | -62.00M |
| AIM ImmunoTech Inc | -4.865M |
| Perspective Therapeutics Inc | 4.776M |
| Protalix BioTherapeutics Inc | 3.59M |
| Armata Pharmaceuticals Inc | -10.83M |